Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

AURA Aura Biosciences Inc

Price (delayed)

$5.95

Market cap

$299.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.9

Enterprise value

$278.55M

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet ...

Highlights
AURA's debt is down by 4.5% YoY
AURA's quick ratio is down by 50% YoY but it is up by 4% from the previous quarter
AURA's equity is down by 39% year-on-year and by 16% since the previous quarter
The company's net income fell by 20% YoY and by 9% QoQ

Key stats

What are the main financial stats of AURA
Market
Shares outstanding
50.27M
Market cap
$299.1M
Enterprise value
$278.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.34
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$102.84M
Net income
-$94.7M
EBIT
-$94.61M
EBITDA
-$91.91M
Free cash flow
-$80.06M
Per share
EPS
-$1.9
EPS diluted
-$1.9
Free cash flow per share
-$1.6
Book value per share
$2.55
Revenue per share
$0
TBVPS
$3.1
Balance sheet
Total assets
$155.4M
Total liabilities
$27.44M
Debt
$18.44M
Equity
$127.97M
Working capital
$122.35M
Liquidity
Debt to equity
0.14
Current ratio
11.06
Quick ratio
10.59
Net debt/EBITDA
0.22
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.7%
Return on equity
-58.6%
Return on invested capital
-57.6%
Return on capital employed
-66.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AURA stock price

How has the Aura Biosciences stock price performed over time
Intraday
14.86%
1 week
13.77%
1 month
10.19%
1 year
-17.36%
YTD
-27.62%
QTD
1.54%

Financial performance

How have Aura Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$102.84M
Net income
-$94.7M
Gross margin
N/A
Net margin
N/A
AURA financials
The company's net income fell by 20% YoY and by 9% QoQ
AURA's operating income is down by 17% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does AURA's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is Aura Biosciences's growth rate over time
AURA growth chart

Valuation

What is Aura Biosciences stock price valuation
P/E
N/A
P/B
2.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Valuation vs average
Price to earnings (P/E)
Aura Biosciences's EPS has decreased by 9% QoQ and by 2.2% YoY
Price to book (P/B)
AURA's equity is down by 39% year-on-year and by 16% since the previous quarter
AURA's price to book (P/B) is 2.5% less than its last 4 quarters average of 2.4
Price to sales (P/S)

Efficiency

How efficient is Aura Biosciences business performance
Aura Biosciences's return on equity has decreased by 40% YoY and by 23% QoQ
The return on assets has declined by 36% year-on-year and by 20% since the previous quarter
AURA's return on invested capital is down by 34% year-on-year and by 25% since the previous quarter

Dividends

What is AURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AURA.

Financial health

How did Aura Biosciences financials performed over time
Assets vs liabilities
AURA's current ratio is down by 50% year-on-year but it is up by 2.7% since the previous quarter
AURA's quick ratio is down by 50% YoY but it is up by 4% from the previous quarter
Debt vs equity
AURA's debt is 86% less than its equity
The debt to equity has surged by 56% year-on-year and by 17% since the previous quarter
AURA's equity is down by 39% year-on-year and by 16% since the previous quarter
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.